Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 133 publications.

Ray KK, Bardet A, Komen J, Manga N, Wolowacz S, Bregantini D, Becker C, Catapano AL. Simulation of long-term impact of bempedoic acid and ezetimibe on atherosclerotic cardiovascular disease outcomes in Europe. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S43. doi: 10.1016/j.jval.2024.10.228

Mody FV, Goyal RK, Ajmera M, Davis KL, Amin AN. Exploring the association between heart rate control and rehospitalization: a real-world analysis of patients hospitalized with heart failure with reduced ejection fraction. Drugs Real World Outcomes. 2024 Sep;11(3):501-11. doi: 10.1007/s40801-024-00436-z

Hohmann C, Manga N, Wolowacz S, Bregantini D, Pfister R. Impact of bempedoic acid on CV outcomes and costs in Germany. Poster presented at the 130th Congress of the German Society of Internal Medicine; April 13, 2024. Wiesbaden, Germany.

Krause T, Fleming A, Hurst M, Zema C, Costello J, Hawe E, Ling C. Prognostic factors and surrogate endpoints in obstructive hypertrophic cardiomyopathy: a systematic literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S36. doi: 10.1016/j.jval.2023.09.189

Toplak H, Bilitou A, Alber H, Auer J, Clodi M, Ebenbichler C, FlieBer-Gorzer E, Gelsinger C, Hanusch U, Ludvik B, Maca T, Schober A, Sock R, Speidl WS, Stulnig TM, Weitgasser R, Zirlik A, Koch M, Wienerroither S, Wolowacz SE, Diamand F, Catapano AL. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients. Wein Klin Wochenschr. 2023 Jul;135(13-14):364-74. doi: 10.1007/s00508-023-02221-4

Katzmann JL, Laufs U, Diamand F, Wolowacz S, Becker C, Bilitou A. Addition of bempedoic acid to the lipid-lowering treatment pathway for high and very high-risk patients in Germany: a simulation study using the SANTORINI observational study cohort. Poster presented at the DGK 89th Annual Meeting; April 13, 2023. Mannheim, Germany.

Mody R, Meyers J, Yu M, Davis K, Levine JA. Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. Curr Med Res Opin. 2022 Nov;38(11):1785-95. doi: 10.1080/03007995.2022.2085962.

Ray KK, Catapano AL, Diamand F, Wolowacz S, Haq I, Bilitou A. Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients. Poster presented at the European Society of Cardiology Congress 2022; August 26, 2022. Barcelona, Spain.

Hawe E, Meleth S, Wolowacz S, Bilitou A. Importance of baseline LDL-C in the association between LDL-C lowering and cardiovascular risk: a meta-regression analysis. Poster presented at the 90th EAS Congress; May 22, 2022. Milan, Italy. [abstract] Atherosclerosis. 2022 Aug; 355:184-5. doi: 10.1016/j.atherosclerosis.2022.06.760

Meyers J, Hoog M, Mody R, Yu M, Davis K. The health care resource utilization and costs among patients with type 2 diabetes and either cardiovascular disease or cardiovascular risk factors an analysis of a US health insurance database. Clin Ther. 2021 Nov;43(11):1827-42. doi: 10.1016/j.clinthera.2021.09.003

Mody R, Meyers J, Yu M, Levine J, Davis KL. Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the U.S. Poster presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.

Wu B, Morland K, Classi P, Sketch MR, Nelson A, Goyal RK, Davis KL, Oudiz R. Economic burden of patients with pulmonary arterial hypertension prior to initiation of treprostinil: a retrospective analysis of US claims. Poster presented at the ATS International 2021 Conference; May 14, 2021.

Aronsson M, Dunton K, Hawe E, Wolowacz S, Quoraishi S, Durrington P, Ray KK, Bilitou A. Building a cost-effectiveness MODEL framework from a payer's perspective to assess NOVEL treatments in primary hypercholesterolaemia and MIXED dyslipidaemia: challenges in a world of LDL-C lowering. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).

Meyers J, Hoog M, Mody R, Yu M, Hasenour C, Davis KL. Burden of cardiovascular disease and cardiovascular (CV) risk in patients with Type 2 diabetes mellitus (T2DM): an analysis of a US health insurance database. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S115. doi: 10.1016/j.jval.2020.04.371

Mody FV, Goyal RK, Ajmera M, Cainzos-Achirica M, Davis KL, Lindstrom RC, Globe G, Riebman JB, Wirtz HS, Amin A. Exploring the association between heart rate control and patient outcomes: a retrospective medical record review of patients hospitalized with systolic heart failure. Poster presented at the 2019 Heart Failure Society of America 23rd Annual Scientific Meeting; September 14, 2019. Philadelphia, PA. [abstract] J Card Fail. 2019 Aug; 25(8 Supplement):S156. doi: 10.1016/j.cardfail.2019.07.447

Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, Das A, Hartley L, Stranges S. Mediterranean‐style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2019 Mar 13;3:CD009825. doi: 10.1002/14651858.CD009825.pub3

Doyle S, Moss E, Hartley L, Knight C, Bell J, Ahdesmaki O, Kelly M. An economic systematic literature review of eosinophilic granulomatosis with polyangiitis. Poster presented at the 2018 ACR/ARHP Annual Meeting; October 22, 2018. Chicago, IL. [abstract] Arthritis Rheumatol. 2018 Sep; 70(S9):1953. doi: 10.1002/art.40700

Luckraz H, Manga N, Senanayake EL, Abdelaziz M, Gopal S, Charman SC, Giri R, Oppong R, Andronis L. Cost of treating ventilator-associated pneumonia post cardiac surgery in the National Health Service: results from a propensity-matched cohort study. J Intensive Care Soc. 2018 May;19(2):94-100. doi: 10.1177/1751143717740804

Jarmul J, Pletcher MJ, Hassmiller Lich K, Wheeler SB, Weinberger M, Avery CL, Jonas DE, Earnshaw S, Pignone M. Cardiovascular genetic risk testing for targeting statin therapy in the primary prevention of atherosclerotic cardiovascular disease: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004171. doi: 10.1161/CIRCOUTCOMES.117.004171

Nagar SP, Rane PP, Fox KM, Meyers J, Davis K, Beaubrun A, Inomata H, Qian Y, Kajinami K. Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. Circ J. 2018 Mar 23;82(4):1008-16. doi: 10.1253/circj.CJ-17-0811

Bhatt M, Ghio M, Nangia A, Sadri L, Plauche L, Dechert T. Understanding the broken heart: risk factors and outcomes for Takotsubo's cardiomyopathy in critically injured trauma patients. Poster presented at the 76th Annual Meeting of the American Association for the Surgery of Trauma and Clinical Congress of Acute Care Surgery; September 2017. Baltimore, MD.

Clar C, Al-Khudairy L, Loveman E, Kelly SAM, Hartley L, Flowers N, Germano R, Frost G, Rees K. Low glycaemic index diets for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017 Jul 31;7:CD004467. doi: 10.1002/14651858.CD004467.pub3

Ogunsola T, Serraro M, Nangia A, Phillips A, MacCallum G, Aragam J, Quin J, Zenati M. Aortic valve replacements: eight year trend at a single institution. Poster presented at the Association of VA Surgeons 41st Annual Surgical Symposium; May 9, 2017. Houston, TX.

Quin J, Nangia A, Tarola C, Serrano M, Gabany J, Sapirstein J, O’Donnell CJ, Haime M, Zenati M. Surgical bioprosthetic aortic valve replacement: discharge anticoagulation practices and one-year survival. Poster presented at the Association of VA Surgeons 41st Annual Surgical Symposium; May 9, 2017. Houston, TX.

Ajmera MR, Goyal RK, Davis KL. Incremental economic burden of cardiometabolic disorders among patients with epilepsy. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A191.

Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or knee replacement: a systematic review. Pharmacoeconomics. 2017 May;35(5):517-35. doi: 10.1007/s40273-017-0486-4

Nagar SP, Fox KM, Rane PP, Beaubrun A, Qian Y, Inomata H, Davis KL, Meyers J, Kajinami K. Incidence of cardiovascular events among secondary prevention patients treated with statins or ezetimibe in Japan. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A261.

Jarmul JA, Pletcher MJ, Earnshaw S, Weinberger M, Jonas D, Avery C, Hassmiller Lich K, Wheeler S, Pignone M. Cardiovascular genetic risk testing for targeting statin therapy in the primary prevention of cardiovascular disease: a cost-effectiveness analysis. Presented at the 2017 (SGIM) Society of General Internal Medicine Annual Meeting; April 20, 2017. Washington, DC.

Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-effectiveness of maintaining daily intake of oat β-glucan for coronary heart disease primary prevention. Clin Ther. 2017 Apr;39(4):804-818.e. doi: 10.1016/j.clinthera.2017.02.012

Kajinami K, Nagar SP, Meyers J, Rane PP, Davis K, Fox KM, Beaubrun A, Inomata H, Qian Y. Treatment utilization patterns and possible statin intolerance among high-risk patients in a real-world Japanese population. Poster presented at the 81st Annual Scientific Meeting of the Japanese Circulation Society; March 19, 2017. Kanazawa, Japan.

Al-Khudairy L, Flowers N, Wheelhouse R, Ghannam O, Hartley L, Stranges S, Rees K. Vitamin C supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017 Mar 16;2017(3). doi: 10.1002/14651858.CD011114.pub2

Wilson M, Lim J, Gandhi P, Wang C, Sander S, McDade C, Earnshaw S. Economic analysis of oral anticoagulants in the prevention of vascular events in Medicare patients with nonvalvular atrial fibrillation. Poster presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 25, 2016. Vancouver, Canada.

Meyers J, Chaudhari P, Madhwani S, Candrilli SD. Clinical and economic burden of peripheral artery disease among patients receiving endovascular interventions: a retrospective cohort study of commercially insured patients in the United States. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A45.

Mitchell S, Roso S, Samuel M, Pladevall-Vila M. Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovasc Disord. 2016 Apr 26;16(1):74. doi: 10.1186/s12872-016-0241-3

Le Moine JG, Fiestas Navarrete L, Katumba K, Launois R. Psychometric validation of the 14 items chronic venous insufficiency quality of life questionnaire (CIVIQ-14): confirmatory factor analysis. Eur J Vasc Endovasc Surg. 2016 Feb;51(2):268-74. doi: 10.1016/j.ejvs.2015.08.020.

Davis KL, Meyers J, Zhao Z, McCollam PL, Murakami M. High-risk atherosclerotic cardiovascular disease in a real-world employed Japanese population: prevalence, cardiovascular event rates, and costs. J Atheroscler Thromb. 2015 Dec 1;22(12):1287-304. doi: 10.5551/jat.28852

Ramamohan V, Mladsi D, Ronquest N, Boklage S. A cost-consequences analysis of inpatient tolvaptan compared with fluid restriction among CHF patients with hyponatremia. Poster presented at the 2015 AMCP Nexus; October 26, 2015. Orlando, FL. [abstract] J Manag Care Pharm. 2015 Oct; 21(10-a):S53.

Martin N, Germano R, Hartley L, Adler AJ, Rees K. Nut consumption for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2015 Sep 28;(9):CD011583. doi: 10.1002/14651858.CD011583.pub2

Hartley L, Clar C, Ghannam O, Flowers N, Stranges S, Rees K. Vitamin K for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2015 Sep 21;(9):CD011148. doi: 10.1002/14651858.CD011148.

Uthman OA, Hartley L, Rees K, Taylor F, Ebrahim S, Clarke A. Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries. Cochrane Database Syst Rev. 2015 Aug 4;(8):CD011163. doi: 10.1002/14651858.CD011163.pub2

Hartley L, Lee MS, Kwong JSW, Flowers N, Todkill D, Ernst E, Rees K. Qigong for the primary prevention of cardiovascular disease (Review). Cochrane Database Syst Rev. 2015 Jun 11;(6):CD010390.

Korsnes JS, Davis KL, Ariely R, Bell C, Mitra D. Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events. J Manag Care Pharm. 2015 Jun;21(6):443-50.

Hartley L, Girling A, Bowater R, Lilford R. A multistudy analysis investigating systematic differences in cardiovascular trial results between Europe and Asia. J Epidemiol Community Health. 2015 Apr;69(4):397-404. doi: 10.1136/jech-2013-203646

Boardman HM, Hartley L, Eisinga A, Main C, Roque i Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015 Mar 10;3:CD002229. doi: 10.1002/14651858.CD002229

Brennan VK, Mauskopf JA, Colosia AD, Copley-Merriman K, Hass B, Palencia R. Utility estimates for patients with type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):111-23.

Brogan AP, Hogue SL, Mordin MM, Kwong J. United States decision maker perceptions of data from observational studies and other health economics and outcomes research. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015; 18:A1-A333.

Hartley L, May MD, Rees K. Dietary fibre for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2015;(1):CD011472. doi: 10.1002/14651858.CD011472.pub2

Bowater RJ, Hartley LC, Lilford RJ. Are cardiovascular trial results systematically different between North America and Europe? A study based on intra-meta-analysis comparisons. Arch Cardiovasc Dis. 2015 Jan;108(1):23-38. doi: 10.1016/j.acvd.2014.03.005

Hartley L, Mavrodaris A, Flowers N, Ernst E, Rees K. Transcendental meditation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014 Dec 1;12:CD010359. doi: 10.1002/14651858.CD010359

Mitchell S, Roso S, Samuel M, Woods MS, Pladevall-Vila M. Targeted literature review of unmet need in the hyperlipidaemia population with high risk of cardiovascular disease. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.